DarioHealth Corp (DRIO)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $14.22M
Last updated: Nov 17, 2026 at 10:57 AM ET
DarioHealth Corp (DRIO) Earnings: Report Dates and Results
DarioHealth (DRIO) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, DarioHealth reported EPS of -$0.73, below the -$0.68 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
DRIO has an expected report date of Mar 17, 2027.
DRIO Earnings Call
The latest DRIO earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, DRIO beat 19 and missed 21. Revenue for the quarter ended Sep 30, 2026 was $5.31M, up 6.0% from $5.01M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.73 | -$0.68 | N/A | -7.35% | Miss | N/A | 2 | 1 up, 0 down | Nov 12, 2026 | $5.31M |
| Jun 30, 2026 | -$0.85 | -$1.19 | N/A | +28.57% | Beat | N/A | 2 | 0 up, 1 down | Aug 11, 2026 | $5.18M |
| Mar 31, 2026 | -$0.95 | -$0.85 | -$0.99 - -$0.71 | -11.76% | Miss | N/A | 2 | 1 up, 0 down | May 13, 2026 | $5.58M |
| Dec 31, 2025 | -$0.77 | -$1.59 | -$1.97 - -$1.16 | +51.86% | Beat | N/A | 3 | 0 up, 1 down | Mar 19, 2026 | $5.23M |
| Sep 30, 2025 | -$2.22 | -$2.42 | -$3.60 - -$1.65 | +8.26% | Beat | N/A | 3 | 0 up, 1 down | Nov 13, 2025 | $5.01M |
| Jun 30, 2025 | -$4.09 | -$2.07 | -$2.40 - -$1.80 | -97.58% | Miss | N/A | 3 | 0 up, 1 down | Aug 12, 2025 | $5.37M |
| Mar 31, 2025 | -$2.38 | -$1.10 | -$1.40 - -$0.80 | -116.36% | Miss | -355.9% | 2 | 0 up, 0 down | May 14, 2025 | $6.75M |
| Dec 31, 2024 | -$0.04 | -$0.23 | N/A | +80.90% | Beat | N/A | 2 | 0 up, 0 down | Mar 10, 2025 | $7.60M |
| Sep 30, 2024 | -$3.67 | -$3.60 | -$7.00 - -$3.20 | -1.94% | Miss | N/A | 3 | 0 up, 0 down | Nov 7, 2024 | $7.42M |
| Jun 30, 2024 | -$4.06 | -$5.80 | N/A | +30.00% | Beat | N/A | 2 | 0 up, 0 down | Aug 8, 2024 | $6.25M |
| Mar 31, 2024 | $0.93 | -$7.40 | -$11.80 - -$4.40 | +112.57% | Beat | N/A | 2 | 1 up, 0 down | May 15, 2024 | $5.76M |
| Dec 31, 2023 | -$0.50 | -$0.55 | N/A | +9.09% | Beat | N/A | 2 | 0 up, 0 down | Mar 28, 2024 | $3.62M |
| Sep 30, 2023 | -$6.48 | -$6.40 | -$12.00 - -$5.00 | -1.25% | Miss | N/A | 4 | 1 up, 0 down | Nov 2, 2023 | $3.52M |
| Jun 30, 2023 | -$8.34 | -$6.00 | N/A | -39.00% | Miss | N/A | 5 | 0 up, 0 down | Aug 10, 2023 | $6.15M |
| Mar 31, 2023 | -$4.90 | -$7.40 | N/A | +33.78% | Beat | N/A | 5 | 0 up, 0 down | May 11, 2023 | $7.07M |
| Dec 31, 2022 | -$0.51 | -$0.65 | -$0.92 - -$0.47 | +21.54% | Beat | N/A | 5 | 2 up, 0 down | Mar 9, 2023 | $6.81M |
| Sep 30, 2022 | -$8.25 | -$11.40 | N/A | +27.63% | Beat | N/A | 7 | 0 up, 0 down | Nov 14, 2022 | $6.61M |
| Jun 30, 2022 | -$14.15 | -$10.40 | N/A | -36.06% | Miss | N/A | 8 | 1 up, 0 down | Aug 15, 2022 | $6.18M |
| Mar 31, 2022 | -$17.05 | -$14.70 | N/A | -15.99% | Miss | N/A | 7 | 0 up, 0 down | May 12, 2022 | $8.06M |
| Dec 31, 2021 | -$1.09 | -$1.06 | -$1.35 - -$0.59 | -2.83% | Miss | N/A | 7 | N/A | Mar 22, 2022 | $6.03M |
| Sep 30, 2021 | -$14.98 | -$15.67 | N/A | +4.40% | Beat | N/A | 6 | N/A | Nov 15, 2021 | $5.63M |
| Jun 30, 2021 | -$17.95 | -$13.56 | N/A | -32.37% | Miss | N/A | 6 | N/A | Aug 16, 2021 | $5.26M |
| Mar 31, 2021 | -$0.92 | -$1.04 | -$2.50 - -$0.59 | +11.54% | Beat | N/A | 6 | N/A | May 17, 2021 | $3.60M |
| Dec 31, 2020 | -$21.20 | -$18.12 | -$19.00 - -$12.40 | -17.00% | Miss | N/A | 5 | N/A | Mar 9, 2021 | $2.08M |
| Sep 30, 2020 | -$14.20 | -$12.10 | -$16.80 - -$11.20 | -17.36% | Miss | N/A | 3 | N/A | Nov 12, 2020 | $2.04M |
| Jun 30, 2020 | -$13.60 | -$30.30 | -$38.00 - -$20.40 | +55.12% | Beat | N/A | 4 | N/A | Aug 12, 2020 | $1.79M |
| Mar 31, 2020 | -$31.40 | -$7.80 | -$22.20 - -$7.80 | -302.56% | Miss | N/A | 2 | N/A | May 12, 2020 | $1.67M |
| Dec 31, 2019 | -$7.72 | -$1.02 | -$1.20 - -$0.84 | -656.86% | Miss | N/A | 2 | N/A | Mar 17, 2020 | $1.80M |
| Sep 30, 2019 | -$24.00 | -$40.00 | -$40.00 - -$32.00 | +40.00% | Beat | N/A | 2 | N/A | Oct 28, 2019 | $1.87M |
| Jun 30, 2019 | -$2.60 | -$2.70 | N/A | +3.70% | Beat | N/A | 2 | N/A | Aug 13, 2019 | $1.65M |
| Mar 31, 2019 | -$60.00 | -$52.00 | -$52.00 - -$52.00 | -15.38% | Miss | N/A | 1 | N/A | May 13, 2019 | $2.24M |
| Dec 31, 2018 | -$2.20 | -$3.00 | N/A | +26.67% | Beat | N/A | N/A | N/A | Mar 25, 2019 | $1.70M |
| Sep 30, 2018 | -$3.40 | -$3.60 | N/A | +5.56% | Beat | N/A | N/A | N/A | Nov 13, 2018 | $1.88M |
| Jun 30, 2018 | -$128.00 | -$72.00 | N/A | -77.78% | Miss | N/A | N/A | N/A | Aug 9, 2018 | $2.06M |
| Mar 31, 2018 | -$80.00 | -$68.00 | -$84.00 - -$68.00 | -17.65% | Miss | -17877.8% | 2 | N/A | May 15, 2018 | $1.76M |
| Dec 31, 2017 | -$25.20 | -$6.00 | -$6.00 - -$6.00 | -320.00% | Miss | N/A | 1 | N/A | Mar 19, 2018 | $1.58M |
| Sep 30, 2017 | -$120.00 | -$122.00 | N/A | +1.64% | Beat | N/A | N/A | N/A | Nov 14, 2017 | $1.38M |
| Jun 30, 2017 | -$172.00 | -$120.00 | N/A | -43.33% | Miss | N/A | N/A | N/A | Aug 14, 2017 | $1.21M |
| Mar 31, 2017 | $0.45 | -$0.30 | N/A | +250.00% | Beat | N/A | N/A | N/A | May 15, 2017 | $1.01M |
| Dec 31, 2016 | -$384.00 | -$184.00 | N/A | -108.70% | Miss | N/A | N/A | N/A | Mar 22, 2017 | $838000 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$9.46, after -$6.84 the year before. It was -$836.00 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$9.46 | N/A |
| Dec 31, 2024 | -$6.84 | N/A |
| Dec 31, 2023 | -$20.22 | N/A |
| Dec 31, 2022 | -$39.96 | N/A |
| Dec 31, 2021 | -$34.94 | N/A |
| Dec 31, 2020 | -$80.40 | N/A |
| Dec 31, 2019 | -$94.32 | N/A |
| Dec 31, 2018 | -$213.60 | N/A |
| Dec 31, 2017 | -$316.75 | N/A |
| Dec 31, 2016 | -$836.00 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,800 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,790 | 10 | |
| 2026Q2 | Jun 30, 2026 | 5,027 | 7 | |
| 2026Q1 | Mar 31, 2026 | 4,832 | 6 | |
| 2025Q4 | Dec 31, 2025 | 5,309 | 7 | |
| 2025Q3 | Sep 30, 2025 | 5,473 | 8 | |
| 2025Q2 | Jun 30, 2025 | 4,701 | 7 | |
| 2025Q1 | Mar 31, 2025 | 5,621 | 6 | |
| 2024Q4 | Dec 31, 2024 | 5,246 | 7 |
2026Q3 Earnings Call
Opening remarks
Zoe Harrison VP, Accounting and Corporate Development Thank you, operator, and good morning, everyone. Thank you for joining us today for a discussion of DarioHealth's Third Quarter of 2026 Financial Results. Leading the call today will be Erez Raphael, Chief Executive Officer of DarioHealth. He'll be followed by John Palumbo, Chairman of the Board; Lara Dodo, our Chief Operating Officer; and Chen Franco, our Chief Financial Officer. An audio recording and webcast replay for today's call will also be available online, as detailed in the press release invite for this call. For the benefit of those who may be listening to the replay or archived webcast, this call is being held on Thursday, November 12, 2026. This morning, we issued a press release announcing our financial results for the third quarter of 2026. A copy of the release can be found on the Investor Relations page of DarioHealth's website. I'd like to remind you that on this call, management will make forward-looking statements within the meaning of the federal securities laws. For example, the company is using forward-looking statements when it discusses expected revenue growth and contribution from signed accounts, the timing and extent of revenue recognition under existing customer agreements, the company's revenue outlook and financial performance expectations, its path to profitability and positive cash flow, the continued reduction in operating expenses and losses, its expansion of channel partnerships and distribution, expected revenue and scaling from partner-led opportunities, expected onboarding, implementation and enrollment of large enterprise accounts, expected conversion of contracted annual recurring revenue into recognized revenue, expected expansion into care delivery, claims-based and outcomes-based models, expected benefit from care delivery partnerships, expected growth in recurring revenue and operating leverage, expected advantages and future impact of DarioIQ and proprietary data assets, expected improvements in member engagement, retention and outcomes, the anticipated benefits of artificial intelligence across the company's commercial operations and internal operations, including expected cost savings, productivity improvements and potential incremental revenue opportunities, the anticipated expansion of existing customer relationships into additional chronic conditions, the expected timing and contribution of new product offerings, the company's ability to increase revenue per customer through its multi-condition strategy, the expected benefits of provider-backed clinical care, the expected timing of revenue acceleration and of activation under health plan agreements, beliefs regarding the convergence of consumer and payer-funded health care and the replatforming of chronic care management, the expected delivery of GLP-1 and other therapies within payer programs and marketplaces, the expected contribution of women's and men's health programs, and beliefs regarding competitive positioning and market opportunity. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the company's control, including the risks described from time to time in its SEC filings.
Frequently Asked Questions About DRIO
When is DarioHealth's next earnings date?
DarioHealth's next earnings report is expected for Mar 17, 2027.
Did DRIO beat earnings estimates last quarter?
No. DarioHealth reported EPS of -$0.73 for the quarter ended Sep 30, 2026, below the -$0.68 estimate by 7.35%.
What EPS do analysts expect from DRIO next quarter?
The consensus EPS estimate for DarioHealth for the quarter ending Dec 31, 2026 is -$0.62 from 5 analysts.
How often does DRIO beat earnings estimates?
DarioHealth beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -7.93%.
DRIO pages: Overview, Earnings, Forecast, Financials, Valuation